Symbols

ARCT

Arcturus Therapeutics·NASDAQ

--(--)

ARCT fundamentals

ARCT Q4 2025 Earnings

Arcturus Therapeutics (ARCT) released its earnings on Mar 3, 2026: revenue was 7.20M (YoY -68.39%), missed estimates; EPS was -1.03 (YoY +7.21%), missed estimates.

Revenue / YoY

7.20M

-68.39%

EPS / YoY

-1.03

+7.21%

Report date

Mar 3, 2026

ARCT Earnings Call Summary for Q4,2025

CF Program Advancement: 12-week Phase II study for ARCT-032 initiated with 10mg dose, targeting 20 patients with advanced endpoints (FEV1, LCI, HRCT).
OTC Regulatory Clarity: Q1 2026 Type C meetings to define pivotal trials for adults and children with OTC deficiency.
Financial Strength: $232.8M cash runway to Q2 2028, despite FY2025 revenue decline driven by LUNAR-COV19 transition.
Innovation Momentum: ARCT-2304 flu vaccine shows durable immunity; STARR® platform validated for rare disease applications.

Earnings

EPS

Revenue

Revenue & Expenses

ARCT has released its 2025 Q4 earnings report, with revenue of 7.20M, reflecting a YoY change of -68.39%, and net profit of -29.08M, showing a YoY change of 3.09%. The Sankey diagram below clearly presents ARCT's revenue sources and cost distribution.

Key Indicators

Arcturus Therapeutics (ARCT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Arcturus Therapeutics (ARCT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Arcturus Therapeutics (ARCT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Arcturus Therapeutics (ARCT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown